$BSGM
BioSig Technologies, Inc. Stock $bsgm

$bsgm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224020634 Filed on May 20, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$14.00K	$5.000K
YoY Change	180.0%	-37.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.882M	$6.245M
YoY Change	-53.85%	-2.44%
% of Gross Profit
Research & Development	$200.0K	$1.100M
YoY Change	-81.82%	-31.97%
% of Gross Profit
Depreciation & Amortization	$78.00K	$84.00K
YoY Change	-7.14%	52.73%
% of Gross Profit
Operating Expenses	$3.451M	$7.391M
YoY Change	-53.31%	-8.45%
Operating Profit	-$3.437M	-$7.386M
YoY Change	-53.47%	-8.42%
Interest Expense	-$3.000K	$4.000K
YoY Change	-175.0%
% of Operating Profit
Other Income/Expense, Net	$25.00K
YoY Change
Pretax Income	-$3.415M	-$7.382M
YoY Change	-53.74%	-8.47%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.402M	-$7.332M
YoY Change	-53.6%	-9.09%
Net Earnings / Revenue	-24300.0%	-146640.0%
Basic Earnings Per Share	-$0.36	-$1.19
Diluted Earnings Per Share	-$0.36	-$0.12
COMMON SHARES
Basic Shares Outstanding	9.856M shares	66.86M shares
Diluted Shares Outstanding	9.856M shares	6.187M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$506.0K	$1.513M
YoY Change	-66.56%	-82.54%
Cash & Equivalents	$416.0K	$1.400M
Short-Term Investments	$90.00K	$101.0K
Other Short-Term Assets		$275.0K
YoY Change		-11.58%
Inventory		$345.0K
Prepaid Expenses	$220.0K	$275.0K
Receivables	$14.00K	$17.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$740.0K	$2.150M
YoY Change	-65.58%	-80.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$182.0K	$630.0K
YoY Change	-71.11%	-46.38%
Goodwill
YoY Change
Intangibles	$1.000K	$1.000K
YoY Change	0.0%
Long-Term Investments	$4.000K	$94.00K
YoY Change	-95.74%
Other Assets	$43.00K	$244.0K
YoY Change	-82.38%	480.95%
Total Long-Term Assets	$849.0K	$3.047M
YoY Change	-72.14%	97.86%
TOTAL ASSETS
Total Short-Term Assets	$740.0K	$2.150M
Total Long-Term Assets	$849.0K	$3.047M
Total Assets	$1.589M	$5.197M
YoY Change	-69.42%	-58.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$5.129M	$2.713M
YoY Change	89.05%	4.51%
Deferred Revenue		$8.000K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.232M	$2.814M
YoY Change	85.93%	3.88%
LONG-TERM LIABILITIES
Long-Term Debt	$500.0K	$0.00
YoY Change
Other Long-Term Liabilities	$60.00K	$368.0K
YoY Change	-83.7%	15.72%
Total Long-Term Liabilities	$560.0K	$368.0K
YoY Change	52.17%	15.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.232M	$2.814M
Total Long-Term Liabilities	$560.0K	$368.0K
Total Liabilities	$5.792M	$3.182M
YoY Change	82.02%	4.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$248.4M	-$223.3M
YoY Change	11.25%
Common Stock	$11.00K	$67.00K
YoY Change	-83.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.321M	$1.976M
YoY Change
Total Liabilities & Shareholders Equity	$1.589M	$5.197M
YoY Change	-69.42%	-58.56%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$3.402M	-$7.332M
YoY Change	-53.6%	-9.09%
Depreciation, Depletion And Amortization	$78.00K	$84.00K
YoY Change	-7.14%	52.73%
Cash From Operating Activities	-$1.300M	-$5.600M
YoY Change	-76.79%	-5.74%
INVESTING ACTIVITIES
Capital Expenditures		$45.00K
YoY Change		-181.82%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$45.00K
YoY Change		-18.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.540M	$6.748M
YoY Change	-77.18%	124.78%
NET CHANGE
Cash From Operating Activities	-$1.300M	-$5.600M
Cash From Investing Activities		-$45.00K
Cash From Financing Activities	$1.540M	$6.748M
Net Change In Cash	$240.0K	$1.103M
YoY Change	-78.24%	-136.84%
FREE CASH FLOW
Cash From Operating Activities	-$1.300M	-$5.600M
Capital Expenditures		$45.00K
Free Cash Flow	-$1.300M	-$5.645M
YoY Change	-76.97%	-4.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Westport
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06880
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	409-5444
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount		usd
CY2024Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue		usd
CY2024Q1	us-gaap	Sales Type Lease Interest Income Lease Receivable SalesTypeLeaseInterestIncomeLeaseReceivable		usd
CY2023Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue		usd
CY2023Q1	us-gaap	Sales Type Lease Interest Income Lease Receivable SalesTypeLeaseInterestIncomeLeaseReceivable		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	BSGM	Class Of Warrant Or Rights Outstanding Intrinsic Value ClassOfWarrantOrRightsOutstandingIntrinsicValue		usd
CY2024Q1	BSGM	Class Of Warrant Or Rights Vested And Expected To Vest Outstanding Intrinsic Value ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue		usd
CY2024Q1	BSGM	Class Of Warrant Or Rights Exercisable Intrinsic Value ClassOfWarrantOrRightsExercisableIntrinsicValue		usd
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	1st Floor
CY2024Q1	dei	City Area Code CityAreaCode	(203)
CY2024Q1	dei	Trading Symbol TradingSymbol	BSGM
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12476413	shares
CY2024Q1	us-gaap	Cash Cash	416000	usd
CY2023Q4	us-gaap	Cash Cash	190000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5000	usd
CY2024Q1	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	90000	usd
CY2023Q4	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	103000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	220000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	206000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	740000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	528000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	509000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	335000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	412000	usd
CY2024Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable SalesTypeAndDirectFinancingLeasesLeaseReceivable	4000	usd
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable SalesTypeAndDirectFinancingLeasesLeaseReceivable	17000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	284000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	288000	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	44000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	44000	usd
CY2024Q1	us-gaap	Assets Assets	1589000	usd
CY2023Q4	us-gaap	Assets Assets	1798000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4821000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4116000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16000	usd
CY2024Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	103000	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	101000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	308000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5232000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4582000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	103000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	560000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	103000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	5792000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4685000	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11165007	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11165007	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9040043	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9040043	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	244085000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241988000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248417000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245015000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4321000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3018000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	13000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	26000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4308000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2992000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1589000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1798000	usd
CY2024Q1	us-gaap	Revenues Revenues	14000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	238000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1062000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2882000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6245000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	253000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	84000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3451000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7391000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3437000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7386000	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3415000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7382000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3415000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7382000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3402000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7332000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	133000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3537000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7334000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.19
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.19
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9856261	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9856261	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6186666	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6186666	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2992000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1251000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1040000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-190000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	133000	usd
CY2024Q1	BSGM	Deemed Preferred Stock Dividend DeemedPreferredStockDividend	133000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3415000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4308000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	292000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	292000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1097000	usd
CY2023Q1	BSGM	Stock Issued During Period Value Issued In Settlement Of Debt StockIssuedDuringPeriodValueIssuedInSettlementOfDebt	105000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	482000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6748000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6748000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	84000	usd
CY2024Q1	BSGM	Non Cash Lease Expense NonCashLeaseExpense	77000	usd
CY2023Q1	BSGM	Non Cash Lease Expense NonCashLeaseExpense	71000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	253000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1061000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2149000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1052000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7382000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1910000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1910000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3415000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7382000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8000	usd
CY2024Q1	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-25000	usd
CY2023Q1	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-25000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5000	usd
CY2024Q1	BSGM	Increase Decrease Customer Deposits IncreaseDecreaseCustomerDeposits	-16000	usd
CY2023Q1	BSGM	Increase Decrease Customer Deposits IncreaseDecreaseCustomerDeposits	8000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	705000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-355000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-84000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-75000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1314000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5648000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	500000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1040000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6748000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1540000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6748000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	226000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1055000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	357000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	416000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1412000	usd
CY2023Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	105000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2000	usd
CY2024Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	133000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
CY2024Q1	us-gaap	Auction Market Preferred Securities Stock Series Liquidation Value AuctionMarketPreferredSecuritiesStockSeriesLiquidationValue	35000000	usd
CY2024Q1	us-gaap	Cash Cash	400000	usd
CY2024Q1	BSGM	Working Capital Deficit WorkingCapitalDeficit	4500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1300000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zue57LGv3LXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zfP9n43NwY56">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Payments For Rent PaymentsForRent	4333	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P30M
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2024Q1	BSGM	Lessor Sales Type Lease Discount Rate LessorSalesTypeLeaseDiscountRate	0.02	pure
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z2tEO2UB7k4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zLyaOcmaSxE4">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2024 and December 31, 2023, deposits in excess of FDIC limits were $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20240331_zPo5TuacIo92" title="Cash, uninsured amount">0.2</span> million and <span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_dxL_c20231231_zlaOSD4OlHO6" title="Cash, uninsured amount::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0679">nil</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	200000	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	43000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	43000	usd
CY2024Q1	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1000	usd
CY2023Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1000	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	44000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	44000	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	253	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1100000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4403383	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1442978	shares
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4752	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4851	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1036000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1452000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	854000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	943000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	182000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	509000	usd
CY2024Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	253411	usd
CY2024Q1	us-gaap	Depreciation Depreciation	73376	usd
CY2023Q1	us-gaap	Depreciation Depreciation	79468	usd
CY2024Q1	BSGM	Number Of Leases NumberOfLeases	2	integer
CY2024Q1	BSGM	Operating Lease Right To Use Assets Gross OperatingLeaseRightToUseAssetsGross	995000	usd
CY2023Q4	BSGM	Operating Lease Right To Use Assets Gross OperatingLeaseRightToUseAssetsGross	995000	usd
CY2024Q1	BSGM	Operating Lease Right To Use Asset Accumulated Depreciation OperatingLeaseRightToUseAssetAccumulatedDepreciation	660000	usd
CY2023Q4	BSGM	Operating Lease Right To Use Asset Accumulated Depreciation OperatingLeaseRightToUseAssetAccumulatedDepreciation	583000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	335000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	412000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	91889	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	92081	usd
CY2024Q1	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	94000	usd
CY2022Q4	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	221000	usd
CY2023Q1	BSGM	Sales Type Lease Invoiced To Customer SalesTypeLeaseInvoicedToCustomer	-30000	usd
CY2023Q1	us-gaap	Sales Type Lease Unguaranteed Residual Asset SalesTypeLeaseUnguaranteedResidualAsset	4000	usd
CY2023Q1	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	195000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4116000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	368000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	452000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	308000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	103000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	278000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	106000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	384000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	368000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	77000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	71000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	6000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	8000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	15000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	92000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	92000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4333	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P30M
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2022	BSGM	Lessor Sales Type Lease Discount Rate LessorSalesTypeLeaseDiscountRate	0.02	pure
CY2023Q4	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	120000	usd
CY2024Q1	BSGM	Sales Type Lease Invoiced To Customer SalesTypeLeaseInvoicedToCustomer	-30000	usd
CY2024Q1	us-gaap	Sales Type Lease Unguaranteed Residual Asset SalesTypeLeaseUnguaranteedResidualAsset	4000	usd
CY2024Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear	78000	usd
CY2024Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	13000	usd
CY2024Q1	us-gaap	Sales Type Lease Unguaranteed Residual Asset SalesTypeLeaseUnguaranteedResidualAsset	4000	usd
CY2024Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	95000	usd
CY2024Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount	1000	usd
CY2024Q1	us-gaap	Sales Type Lease Net Investment In Lease SalesTypeLeaseNetInvestmentInLease	94000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1608000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1277000	usd
CY2024Q1	BSGM	Accrued Reimbursements Current AccruedReimbursementsCurrent	9000	usd
CY2023Q4	BSGM	Accrued Reimbursements Current AccruedReimbursementsCurrent	9000	usd
CY2024Q1	BSGM	Accrued Consulting Current AccruedConsultingCurrent	682000	usd
CY2023Q4	BSGM	Accrued Consulting Current AccruedConsultingCurrent	804000	usd
CY2024Q1	BSGM	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	812000	usd
CY2023Q4	BSGM	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	802000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	334000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	333000	usd
CY2024Q1	BSGM	Accrued Office Expense And Other Expense AccruedOfficeExpenseAndOtherExpense	704000	usd
CY2023Q4	BSGM	Accrued Office Expense And Other Expense AccruedOfficeExpenseAndOtherExpense	290000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	672000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	601000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4821000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	BSGM	Deemed Dividend DeemedDividend	132931	usd
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11165007	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11165007	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9040043	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9040043	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	543479	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M
CY2024Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	402705	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	603229	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.67
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	59750	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.92
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	543479	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.19
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	402705	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	31.12
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	0.661
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2682	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	257187	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	178967	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y3M21D
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2878734	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.40
CY2023	BSGM	Warrants Granted Weighted Average Remaining Contractual Term WarrantsGrantedWeightedAverageRemainingContractualTerm	P3Y8M12D
CY2023Q4	BSGM	Class Of Warrant Or Rights Outstanding Intrinsic Value ClassOfWarrantOrRightsOutstandingIntrinsicValue	1717104000	usd
CY2024Q1	BSGM	Class Of Warrants Or Right Issued ClassOfWarrantsOrRightIssued	130363	shares
CY2024Q1	BSGM	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	3.36
CY2024Q1	BSGM	Warrants Weighted Average Remaining Contractual Term Issued WarrantsWeightedAverageRemainingContractualTermIssued	P5Y3M18D
CY2024Q1	BSGM	Class Of Warrants Or Right Exercised ClassOfWarrantsOrRightExercised	2878734	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.21
CY2024Q1	BSGM	Warrants Granted Weighted Average Remaining Contractual Term WarrantsGrantedWeightedAverageRemainingContractualTerm	P3Y7M6D
CY2024Q1	BSGM	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Vested And Expected To Vest Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding	7.21
CY2024Q1	BSGM	Warrants Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P3Y7M6D
CY2024Q1	BSGM	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable	7.46
CY2024Q1	BSGM	Warrants Exercisable Weighted Average Remaining Contractual Term WarrantsExercisableWeightedAverageRemainingContractualTerm	P3Y4M24D
CY2024Q1	us-gaap	Share Price SharePrice	0.661
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder.
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2650071	shares
CY2024Q1	BSGM	Net Income Loss Of Non Controlling Interest NetIncomeLossOfNonControllingInterest	-44000	usd
CY2024Q1	BSGM	Average Noncontrolling Interest Percentage Of Profitlosses AverageNoncontrollingInterestPercentageOfProfitlosses	0.30	pure
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13000	usd
CY2023Q1	BSGM	Net Income Loss Of Non Controlling Interest NetIncomeLossOfNonControllingInterest	-161000	usd
CY2023Q1	BSGM	Average Noncontrolling Interest Percentage Of Profitlosses AverageNoncontrollingInterestPercentageOfProfitlosses	0.31	pure
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	26000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	13000	usd
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	21694	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	65919	usd
CY2024Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1759385	usd
CY2023Q4	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	775782	usd
CY2024Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	1440000	usd
CY2024Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	144000	usd
CY2024Q1	us-gaap	Revenues Revenues	14000	usd
CY2023Q1	us-gaap	Revenues Revenues	5000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3451000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7391000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3437000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7386000	usd
CY2024Q1	us-gaap	Assets Assets	1589000	usd
CY2023Q4	us-gaap	Assets Assets	1798000	usd

Files In Submission

Name	View Source	Status
0001493152-24-020634-index-headers.html	Edgar Link	pending
0001493152-24-020634-index.html	Edgar Link	pending
0001493152-24-020634.txt	Edgar Link	pending
0001493152-24-020634-xbrl.zip	Edgar Link	pending
bsgm-20240331.xsd	Edgar Link	pending
ex31-01.htm	Edgar Link	pending
bsgm-20240331_def.xml	Edgar Link	unprocessable
ex31-02.htm	Edgar Link	pending
ex32-01.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bsgm-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bsgm-20240331_lab.xml	Edgar Link	unprocessable
bsgm-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BSGM
BioSig Technologies, Inc. Stock $bsgm

2024 Q1 Form 10-Q Financial Statement

#000149315224020634 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BSGM BioSig Technologies, Inc. Stock $bsgm

2024 Q1 Form 10-Q Financial Statement

#000149315224020634 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BSGM
BioSig Technologies, Inc. Stock $bsgm